Abstract
Objective Circulating fibrocytes are elevated in idiopathic pulmonary fibrosis, but the relationship between fibrocyte level with lung function decline and outcomes is lacking replication in prospective clinical study. We aim to validate the utility of circulating fibrocyte levels as a prognostic biomarker in idiopathic pulmonary fibrosis.
Methods We tested associations between circulating fibrocyte levels, mortality, disease progression and longitudinal lung function in a well-defined prospective observational study of pulmonary fibrosis (PROFILE; NCT01134822). A subset of recruited participants had blood samples processed for fibrocyte measurement, with flow cytometry based on CD45 and collagen-I gating. Associations were tested using univariable and multivariable generalised linear models. Mortality data were subsequently combined with an independent cohort in a mixed-effect multilevel analysis.
Results In 102 participants with idiopathic pulmonary fibrosis, an empirically defined cutpoint of 2.22% was associated with a greater risk of overall mortality in adjusted analysis (Hazard Ratio 2.24 95% CI 1.06-4.72). A 2.5 fold greater risk of mortality was supported in a pooled analysis with a historic cohort for a larger sample of 162 participants of idiopathic pulmonary fibrosis, specifically (Hazard Ratio 2.49 95% CI 2.41-2.56). A previously defined mortality risk threshold of 5% circulating fibrocytes was not reproducible in this cohort, circulating fibrocytes were not significantly elevated above non-specific interstitial pneumonia or healthy controls.. We found no association of fibrocytes with lung function or disease progression.
Conclusions In a prospective clinical cohort of idiopathic pulmonary fibrosis, circulating fibrocytes of 2.22% or above are associated with greater mortality, but do not associate with disease related decline in lung function.
What is the key question?Can circulating fibrocytes provide reproducible prognostic biomarker value in fibrotic lung disease?
What is the bottom line?Greater proportions of fibrocytes isolated from circulating leukocyte populations are associated with an increase risk of mortality in idiopathic pulmonary fibrosis, but no association was observed with disease related decline in lung function.
Why read on?We present associations and limitations of circulating fibrocytes in the largest sample of individuals with pulmonary fibrosis, recruited into a prospective observational study, and replicate prognositic insights from a historic cohort.
Competing Interest Statement
TMM has, via his institution, received industry-academic funding from GlaxoSmithKline and UCB as well as consultancy or speakers fees from AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, GlaxoSmithKline, ProMetic, Roche, Sanumed and UCB as well as stock options from Apellis, outside the submitted work. TMM has received industry-academic funding from GlaxoSmithKline (GSK) R&D, UCB, and Novartis and has received consultancy or speakers fees from AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, GSK R&D, Lanthio, InterMune, ProMetic, Roche, Sanofi-Aventis, Takeda, and UCB. RGJ reports grants from GlaxoSmithKline, the UK Medical Research Council, Biogen, Galecto and MedImmune as well as personal fees from Boehringer Ingelheim, GlaxoSmithKline, InterMune, MedImmune, PharmAkea, Roche and Pulmatrix, outside the submitted work; he has served as a consultant for Pliant Therapeutics and MuMedii and a trustee for the charities Action for Pulmonary Fibrosis and the British Thoracic Society. RGJ has received industry-academic funding from Galecto, GSK R&D, MedImmune, Novartis, and Biogen and has received consultancy or speakers fees from Biogen, Boehringer Ingelheim, GSK R&D, InterMune, MedImmune, PharmAkea, Pulmatrix, and Roche.
Clinical Trial
NCT01134822
Funding Statement
This work was funded by grants from GSK, UK MRC and NIHR grants.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval from University ethics committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This article has an online data supplement
Clarification of the analysis as a validation study of the original Moeller study, and transparent demonstration of lack of reproducibility of 5% threshold. Empirical endpoint defined using PROFILE data and modelled with both datasets. Figures revised, inclusion of figure 2 and figure 3 to demonstrate survival and hazard ratios across datasets. Message focussed on IPF.
Data Availability
Data is available from the Study Steering Committee at reasonable request
